The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•13 February 2026•

1 min read

Charles River Stock Plummets 17.7% as Biopharma Spending Weakens

Charles River Laboratories International (CRL) shares experienced a significant 17.7% decline within a five-day trading period, reflecting intense selling pressure. The company is currently grappling with negative revenue growth and a deeply negative P/E ratio of -97.8, highlighting severe financial headwinds. Market analysts attribute this downturn to a combination of project cancellations and a broader slowdown in biopharma industry spending. Furthermore, a strategic industry shift away from traditional animal testing models is creating long-term structural challenges for the firm's core operations. This underperformance stands in stark contrast to industry peers such as LabCorp (LH) and Thermo Fisher Scientific (TMO). Given the current operational hurdles and negative financial metrics, the outlook for CRL remains cautious as it navigates these significant industry-wide shifts.